Jim Cramer sees trouble coming in Apple’s earnings report next week. » Read More
Recently, a number of companies' corporate insiders have bought large amounts of stock. These insiders are finding some value in the market, which warrants a closer look at these stocks, theStreet.com reports.
J.D. Power reports new cars have fewer mechanical problems, with CNBC's Phil LeBeau.
JPMorgan has sold off 65-70% of its losing "London Whale" position, with CNBC's Kate Kelly.
Procter & Gamble has lowered its Q4 earnings and revenue forecasts, with the Fast Money traders.
Stocks hit their session lows after the Fed announcement and then rebounded, with the Fast Money traders. CNBC's Ron Insana, and David Kelly, JPMorgan, weigh in.
The Fed has left rates unchanged, adding that the economy has expanded moderately, but growth in employment has slowed, with CNBC's Hampton Pearson, Rick Santelli, Steve Liesman & Bob Pisani; Bill Gross, Pimco; Charles Reinhard, Morgan Stanley; and Ken Volpert, Vanguard.
Take a look at some of Wednesday's midday movers:
In a matter of hours, we will know what the Fed will or won't do to aid the U.S. economy. Here's a trading plan.
The telecommunications industry has attracted investors seeking shelter from historically low yields from fixed income investments as well as the uncertainties stemming from Europe's continuing crisis and the volatility its created in U.S. markets, TheStreet.com reports.
U.S. stock index futures pointed to a mixed open on Wall Street on Wednesday as investors turned their attention away from the G20 Summit and the euro zone crisis and concentrated instead on domestic concerns.
Take a look at some of Wednesday’s morning movers:
"I'd like to see the Fed stand pat, I think they are more likely to do an Operation Twist," says Peter Fisher, BlackRock global head of fixed income, discussing the odds of additional Fed easing when officials wrap its two-day meeting today.
Former Minnesota Governor Jesse Ventura explains why he thinks U.S. politics and the government has become its own 'gangsta's paradise.'
A new study from RBC Capital and Capgemini says the past year has been tough on not only the poor, but the rich, reports CNBC's Robert Frank. Hugh Hewitt, The Hugh Hewitt Show host, weighs in.
Mad Money host Jim Cramer shares his final thoughts of the day.
Ron Cohen, Acorda Therapeutics president & CEO, offers insight on just how much potential his company's multiple sclerosis drug "AMPYRA" has in the pharmaceutical market.
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
How do investors know the difference between a horrible decline and a buyable pullback? Mad Money host Jim Cramer, takes a look at Nike's 10% decline in the last 6 weeks as an example.
Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses his company's efforts to develop treatment products for Lysosomal Storage Disorders. "We are the opposite of big pharma, we look at a significant improvement in a small patient population," says Bienaime.
Mad Money host Jim Cramer says today's rally was a glimpse of what could happen if the European mess ever gets resolved.